Skip to main content
. 2021 Jul 8;12:670081. doi: 10.3389/fphar.2021.670081

FIGURE 6.

FIGURE 6

Anti-tumor effect of triclabendazole in the xenograft model. BALB/C nude mice are injected subcutaneously with 1 × 106 MDA-MB-231 breast cancer cells into their right flanks and then injected intraperitoneally with triclabendazole (20 mg/kg or 100 mg/kg) or vehicle. (A) Tumor in BALB/C nude mice. (B) Image of MDA-MB-231–derived xenograft tumors at the end of the study. The nude mice are sacrificed after 2 weeks of treatment with triclabendazole, and then the tumors are carefully dissected and photographed (n = 6). (C) Curves of tumor size. Data are shown as mean ± SD (n = 6); statistical analysis is performed by two-way ANOVA. (D) Western blot analyzing protein expression of cleaved caspase-3, cleaved PARP, and GSDME in tumors derived from treatment with triclabendazole or vehicle. (E) Immunohistochemical analysis of protein expression of cleaved caspase-3 in tumor sections (n = 3); images are captured by the Leica microscope, and representative images are shown. Scale bars: 20 μm. ***p < 0.001; TRI, triclabendazole.